



Press release 2015-04-16

Order intake totaled 22.1 MSEK during Q1

C-RAD AB, with its three fully owned subsidiaries and three international sales companies, are all active in the field of radiation therapy. Just prior to its Annual General Meeting C-RAD is presenting the order intake and revenue for the first quarter of fiscal year 2015.

The order intake for C-RAD totaled 22.1 MSEK during the first quarter of fiscal year 2015. Orders for Positioning Products (which includes Sentinel, Catalyst and Cyrpa lasers) and related service products increased by 127%.

Revenues for the entire group amounted to 15.1 MSEK in the same period. This is an improvement of 40% compared to the first quarter of 2014.

In previous years the annual frame order for the production of IBA dosimetry equipment was booked in the first quarter. Since C-RAD decided in 2014 to focus its resources on its own products, this frame order is not included in the Q1 2015 order intake.

C-RAD management decided to disclose order intake and revenue information prior to the annual general meeting. The comprehensive interim report for the first quarter will be published on May 8, 2015.

“We are very satisfied with the positive development and the increasing interest of our customers in C-RAD’s superior patient positioning solutions,” says Tim Thurn, CEO of C-RAD. “With an appealing product portfolio, a motivated sales team and a customer-centered service organization we will take on the challenge of fulfilling our ambitious targets for 2015 and beyond.”

About C-RAD

C-RAD develops innovative solutions for use in advanced radiation therapy. The C-RAD group offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries: C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB, all of which are located in Uppsala, Sweden. Employees currently number 31. C-RAD’s business originates from research and development at Karolinska Institutet in Solna, Sweden. Sales of the company’s first product, the C-RAD Sentinel™, started in 2007. Cooperation agreements have been signed with Elekta (Sweden), Varian (USA) and IBA (Belgium). C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD has established three companies for direct sales: C-RAD Inc. in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. C-RAD holds 29% of the shares in laser company Cyrpa with an option to acquire the remaining 71%. C-RAD AB is listed on NASDAQ Stockholm.

For more information on C-RAD, please visit www.c-rad.com.

For further information:

Tim Thurn, CEO C-RAD AB, Phone +46-18-666930, Email investors@c-rad.com

The revenue figures cited may be subject to slight changes due to exchange rates and accounting reasons.



The above information is price-sensitive and must therefore be disclosed under the Securities Market Act (2007:528).

